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A Dual Killing Strategy — Photocatalytic Generation of Singlet 
Oxygen with Concomitant Pt(IV) Prodrug Activation 
Daniel Norman,[a] Alessia Gambardella[a], Andrew Mount[a], Alan Murray[b] and Mark Bradley* [a] 
 
Abstract: A Ruthenium-based mitochondrial-targeting 
photosensitiser that undergoes efficient cell uptake, enables the rapid 
catalytic conversion of Pt(IV) prodrugs into their active Pt(II) 
counterparts and drives the generation of singlet oxygen was 
designed. This duality drives two orthogonal killing mechanisms with 
cytotoxicity mediated with temporal and spatial control and was shown 
to elicit cell death of a panel of cancer cell lines including those 
showing oxaliplatin-resistance.  
Photodynamic therapy (PDT) utilizes photosensitisers (PS) in 
combination with illumination to generate cytotoxic reactive 
oxygen species (ROS); primarily singlet oxygen (1O2)[1]. As this 
only occurs in areas where light is focused, it enables spatially 
selective cytotoxic effects. Clinical applications of PDT include 
skin tumors[2] and head and neck cancers[3] as these are optically 
readily accessible. 
Several porphyrin-based photosensitisers have been approved 
for clinical use including photofrin[4], however it has serious side-
effects in that patients may exhibit severe photosensitivity[5], as 
well as non-specific damage to surrounding healthy tissue[6]. 
Recently, a ruthenium-based photosensitiser, TLD-1433, 
completed Phase Ib clinical studies for bladder cancer treatment. 
This trial demonstrated the safety of this PS and also the utility of 
PDT at wavelengths outside of the “optimal window” with cancers 
that may not be considered optically accessible[7].  
A related therapeutic concept involves photo-activatable prodrugs, 
whereby irradiation generates a cytotoxic drug from an inert 
prodrug[8]. Of relevance are the Pt-based photo-activatable 
prodrugs developed by Sadler et al[9] where irradiation of a 
diazido-Pt(IV) complex gives rise to the cytotoxic Pt(II) 
counterpart, eliciting a dramatic increase in cytotoxic effect, ideal 
for photo-activated chemotherapy applications. Riboflavin has 
also been shown to be an effective photocatalyst for the 
conversion of Pt(IV) complexes to their cytotoxic Pt(II) 
counterparts[10] (for other Pt(IV) approaches see review by 
Lippard et al[11]). 
Herein, we report the design, synthesis and evaluation of a 
photocatalytic Pt(IV) prodrug activation platform capable of 
reducing Pt(IV) prodrugs while simultaneously generating singlet 
oxygen (Scheme 1). The Pt(IV) prodrugs were designed to be  
 “bio-inert” prior to photochemically-induced reduction, while the 
photosensitiser (PS-1) was shown to be taken up rapidly by cells 
and localized in the mitochondria. Upon irradiation at 470 nm, the 
photosensitisers were capable of activating Pt(IV) prodrugs, while 
also causing significant oxidative damage to cells, thus affording 
a spatially- and temporally-controlled cytotoxic effect. The ability 
of this Pt(IV) prodrug activation system to overcome drug 
resistance was explored. While the commercial photosensitiser, 
Ru(bpy)3Cl2, was found to be capable of reducing Pt(IV) species, 
it had limited cell uptake. Therefore, a derivative, PS-1, was 
synthesized by addition of 1,3,3-trimethyl-2-methyleneindoline to 
4-formylphenyl boronic acid (Scheme 2), followed by Suzuki-
Miyaura coupling with 4-bromo-2,2’-bipyridine to afford the 
desired ligand that was treated with Ru(bpy)2Cl2 with replacement 
of the chloro ligands driven by microwave heating.  
 
Scheme 1. Representation of the photocatalytic conversion of 
Pt(IV) prodrugs to their active Pt(II) counterparts by a Ru(II) 
photocatalyst with simultaneous 1O2 generation.  
Ruthenium-based photosensitisers generally display 
characteristic light absorption profiles[12] due to ligand-to-ligand 
(π-π*) and metal-to-ligand (dπ-π*) charge transfer bands and 
these were observed for PS-1 (Figure S1). The singlet oxygen 
quantum yield of PS-1 was quantified by the Singlet Oxygen 
Sensor Green (SOSG) assay[13] and found to be 0.72 (compared 
to 0.88 for Ru(bpy)3Cl2[14]) (Figure S2). In the presence of a Pt(IV) 
complex (Pt-c), the quantum yield reduced to 0.37. The photo-
activation of the Pt(IV) species was desired to occur intracellularly 
so cellular uptake of PS-1 was determined by ICP-MS. PS-1 was 
observed to be taken up well by all three cell lines used, with 62-
90% of the compound added to the culture media taken up into 
the cells after 4 h (see Table 1). The high cellular uptake of PS-1 
attributed to the positively charged indoline moiety and the 
lipophilic nature of the ligands, facilitating passage across the 
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negatively charged cell membrane; a feature that can be 
accentuated in cancer cells [15]. The stability of PS-1 in complex 
media was demonstrated by incubation in 10% FBS in DMEM 
(Figure S3). 
The ability of PS-1 to elicit cell death upon illumination of light was 
confirmed in SKOV-3-wt cells (Figure S4). In the dark, PS-1 has 
negligible effects on cell viability whereas when illuminated it 
generates cytotoxic reactive oxygen species (IC50: 17 µM). 
To identify a “bio-inert” Pt(IV) prodrug, a series of symmetrical and 
non-symmetrical Pt(IV) complexes, Pt-a to Pt-g, were 
synthesized using standard conditions and screened against 
biological reductants to identify Pt(IV) prodrugs that were resistant 
to the biological reductants glutathione (GSH) and ascorbic acid 
(AsA) (Figure S5). 
The non-symmetrical Pt(IV) complexes carrying an axial acetate 
ligand and either tert-butanoate or benzoate axial ligands (Pt-c 
and Pt-d) were stable to reduction by glutathione or ascorbic acid.  
Symmetrical complexes with increased steric hindrance, (Pt-f and 
Pt-g) were ineffective at preventing reduction. Electron-
withdrawing axial ligands, such as trifluoroacetate (Pt-b and Pt-e) 
were unstable towards biological reductants, presumably due to 
destabilisation of the Pt(IV) center as has been observed 
previously[16]. Pt-e has also previously been shown to hydrolyze 
in solution to Pt-b expediting further reduction[17]. Prior work 
correlating trends of physicochemical properties of Pt(IV), such as 
reduction potential or logP have shown possible links to biological 
stability or activity[18]. Analyses of the reduction potentials of Pt-a 
to Pt-g, showed that Pt-c had the highest reduction potential (-
0.90 V) which may confer its stability towards biological 
reductants (Figure S6 and Table S5). However, this is not the only 
determinant factor as similar reduction potentials were observed 
for Pt-f and Pt-g (-0.86 V and -0.74 V, respectively), which were 
not stable towards biological reductants. 
The complex Pt-d exhibited low water solubility and was 
discontinued from further studies with Pt-c taken forwards. Pt-c 
was also found to be relatively stable in 10% FBS in DMEM, as 
measured by HPLC (Figure S7). The difference in cytotoxicity of 
Pt-c compared to the clinical drug, oxaliplatin (OxPt), was 
analysed in HCT116 and SKOV-3-wt cells, showing that Pt-c 
exhibited significantly reduced cytotoxicity compared to the parent 
drug with IC50’s of 64 vrs 9 µM for SKOV-3-wt and 97 vrs 6 µM for 
HCT116 cells (Figure S8).  
The cellular uptake of Pt-c (as quantified by ICP-MS, Table 1) 
showed much greater uptake of the Pt(IV) prodrug than of OxPt, 
as is commonly observed in comparisons of Pt(II) and Pt(IV) 
complex cell uptake, as the Pt(IV) oxidation state affords more 
substitution-inert complexes than Pt(II) complexes[19], thereby 
enabling passage into cells without degradation or attack by 
biomolecules. The increased lipophilicity may also be responsible 
for promoting cellular uptake, although trends between cLogP and  
 cellular accumulation of Pt complexes are often poorly 
correlated[20]. 
The ability of PS-1 to photocatalytically reduce the Pt(IV) prodrug 
Pt-c into OxPt was confirmed, as shown in Figure 1, with Pt-c 
reduced into OxPt by 2 mol% PS-1 by illumination (λ = 470 nm, 
0.58 mW.cm-2), with 88% conversion observed after 60 min of 
illumination (Figures S9-S11) with the conversion of Pt-c to OxPt 
also confirmed by NMR (Figure 1b and Figure S12). 
To quantify the level of cell death brought on by photoactivation 
of Pt-c and the dual oxidative damage inflicted by PS-1 SKOV-3-
wt and HCT116 cell lines were incubated with PS-1 and Pt-c and 
irradiated. 
Scheme 2. Synthesis of the photocatalyst PS-1 and the Pt(IV) prodrugs Pt-a to Pt-g. 
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Cells that did not undergo irradiation showed little cell death when 
incubated with either PS-1 or PS-1 with Pt-c (Figure 2b). 
Whereas when PS-1 was used in conjunction with illumination 
there was significantly reduced cell viability, due to the generation 
of 1O2 and other reactive oxygen species. To verify this, the singlet 
oxygen generation in cells was measured by co-incubation of 
SOSG and the turn-on of fluorescence tracked over time (Figure 
S13). 
The combination of PS-1 and Pt-c with illumination demonstrated 
very high levels of light-mediated cytotoxicity in both SKOV-3-wt 
and HCT116 cell lines. Due to the high uptake of PS-1 and the 
increased uptake of Pt-c compared to OxPt and the efficacy of 
the photocatalysed Pt(IV) prodrug activation, it was hypothesised 
that light-mediated photocatalytic activation of Pt-c may be able 
to overcome the acquired resistance to OxPt. To explore this, 
SKOV-3-wt cells were allowed to accrue resistance to oxaliplatin 
by sub-culturing in incremental doses of OxPt over 3 months 
(procedure in ESI). The IC50 for OxPt in wild-type SKOV-3 (SKOV-
3-wt) cells was 8.8 µM, which increased some 3-fold to 25 µM for 
the more resistant cells (SKOV-3-OxR). The Pt(IV) prodrug Pt-c 
again exhibited reduced cytotoxicity compared to its Pt(II) 
counterpart, OxPt, with IC50 values of 82 vrs 25 µM in the SKOV-
3-OxR cells. 
Photocatalytic activation of Pt-c in SKOV-3-OxR cells elicited 
substantial cell death, albeit with a slightly diminished cytotoxic 
effect than in SKOV-3-wt. Harvesting of the cellular DNA was 
performed 24 h post-photocatalytic activation of Pt-c in SKOV-3-
wt and SKOV-3-OxR cells with the Pt content of each analysed 
by ICP-MS. There was a marked increase in platinated DNA in 
SKOV-3-wt and SKOV-3-OxR cells when PS-1 and Pt-c were 
utilised in conjunction with light irradiation compared to controls 
(Figure S14). Interestingly, there was a larger overall platinated 
DNA content for SKOV-3-OxR (acquired resistance to oxaliplatin) 
than with either OxPt or photocatalysed Pt(IV)-Pt(II) conversion 
compared to SKOV-3-wt i.e. naïve cells towards oxaliplatin. As 
the photosensitiser was found to primarily localize in the 
mitochondria (Figure 2a and S15), cellular fractionation (into 
cytosol, mitochondrial and nuclear fractions) followed by ICP-MS 
analysis was used to probe the localization of the Pt(IV) prodrug 
in SKOV-3-wt cells (Figure S16). Pt-c was found mainly in the 
cytosolic fraction but was distributed throughout the cell, with 
slightly lower levels in the mitochondria and the nucleus. This ratio 
of distribution did not appear to be altered by the co-incubation of 
PS-1. 
Finally, to explore the scope of this Pt(IV) prodrug activation 
system, the ability of two ruthenium-based photosensitisers to 
reduce three different Pt(IV) species was shown (Figure S17). 
TLD-1433, a photosensitiser currently under clinical investigation, 
was capable of reducing two oxaliplatin Pt(IV) species upon 
illumination of light. This was also shown to be possible with other 
platinum drugs, such as a Pt(IV) cisplatin derivative (Cpt-Ac). 
In conclusion, a photocatalytic platform for the simultaneous 
activation of Pt(IV) prodrugs and generation of singlet oxygen has 
been developed utilising a ruthenium-based photosensitiser. This 
system demonstrated excellent cytotoxic capabilities following 
illumination of cancer cell lines. The prodrug activation system 
overcame acquired Pt resistance in cells and demonstrated 
robustness in each of the cell lines used. The catalytic activation 
of Pt(IV) with concomitant singlet oxygen generation thus allows 
Table 1. Cellular uptake of PS-1 and Pt-c as measured by ICP-
MS 
Compound[a] Cell Line Cell Uptake (ng/106 cells)[%][b] 
PS-1 SKOV-3-wt 275 ± 9 (90 ± 3%) 
 SKOV-3-OxR 191 ± 3 (63 ± 1%) 
 HCT116 190 ± 10 (63 ± 3%) 
Pt-c SKOV-3-wt 531 ± 20 (14 ± 0.5%) 
 SKOV-3-OxR 384 ± 2 (10 ± 0.04%) 
 HCT116 458 ± 12 (12 ± 0.3%) 
OxPt SKOV-3-wt 161 ± 11 (1 ± 0.9%) 
 SKOV-3-OxR 
 
HCT116 
150 ± 5 (1 ± 0.4%) 
 
281 ± 10 (2 ± 0.8%) 
 
[a] Cells were incubated with either PS-1 (1 µM) or Pt-c (20 µM) for 4 h 
at 37°C (n = 3)  
[b] % uptake calculated as proportion of the theoretical maximal 
uptake. 
Figure 1. Analysis of the reduction of Pt-c by PS-1: (a) HPLC 
analysis of the photo-reduction (λ = 470 nm, 0.58 mW.cm-2) of Pt-
c (50 µM) by PS-1 (1 µM) in PBS over time. (b) NMR analysis 
following the conversion of the Pt(IV) prodrug Pt-c (100 µM) into 
oxaliplatin (Pt(II)) in D2O by monitoring the resonances correlating 
to the protons of the diaminocyclohexyl ligands. 
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low dosing of photosensitiser which may help reduce  
phototoxicity-related side-effects. The composition of the 
photosensitiser will be further explored in terms of extending the 
absorption wavelength to more therapeutically applicable ranges 
through modification of the ligands and further enhancing the 
cancer-targeting capabilities of photocatalytic compounds that 
can be used for Pt(IV) prodrug activation 
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